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Netherton syndrome (NTS) is an autosomal recessive congenital ichthyosis featuring chronic inﬂammation of the
skin, hair anomalies, epidermal hyperplasia with an impaired epidermal barrier function, failure to thrive and atopic
manifestations. The disease is caused by mutations in the SPINK5 gene encoding the serine proteinase inhibitor
lympho-epithelial Kazal-type inhibitor (LEKTI). Sequence analyses of SPINK5 in seven NTS patients from ﬁve
different families allowed us to identify two known and three novel mutations all creating premature termination
codons. We developed a monoclonal antibody giving a strong signal for LEKTI in the stratum granulosum of
normal skin and demonstrated absence of the protein in NTS epidermis. Immunoblot analysis revealed presence of
full length LEKTI and of LEKTI cleavage fragments in normal hair roots, whereas in NTS hair roots LEKTI and its
cleavage products were completely missing. Transglutaminase1 activity was present throughout almost the entire
suprabasal epidermis in NTS, whereas in normal skin it is restricted to the stratum granulosum. In contrast,
immunostaining for transglutaminase3 was absent or faint. Moreover, comparable with the altered pattern in
psoriatic skin the epidermis in NTS strongly expressed the serine proteinase inhibitor SKALP/elaﬁn and the anti-
microbial protein human b-defensin 2. These studies demonstrate LEKTI deﬁciency in the epidermis and in hair
roots at the protein level and an aberrant expression of other proteins, especially transglutaminase1 and 3, which
may account for the impaired epidermal barrier in NTS.
Key words: elafin/epidermal barrier/genetics/human b-defensin 2/mutation/Netherton syndrome/serine protei-
nases/skin/transglutaminase
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Netherton syndrome (NTS), a rare autosomal recessive
genodermatosis, combines chronic and severe inflamma-
tion of the skin with hair shaft anomalies and atopic
features. The degree of skin involvement varies, some
patients show severe congenital ichthyosiform erythroder-
ma (CIE), whereas most present with ichthyosis linearis
circumflexa (ILC)––polycyclic migrating plaques with char-
acteristic double-edged scales (Traupe, 1989). Often pa-
tients display at birth CIE, which in some of them improves
and evolves into ILC. The finding of trichorrhexis invaginata
(‘‘Bamboo hairs’’) is diagnostic (Sybert, 1997). These and
other hair anomalies (pili torti, trichorrhexis nodosa),
however, are not always present and even repeated hair
samples may be negative. Other conditions often asso-
ciated with NTS are delayed growth, recurrent infections,
urticaria, angioedema, failure to thrive, aminoaciduria, and
in some instances slight mental retardation (Greene and
Muller, 1985).
Because of the variable expression of skin signs and
delayed onset of characteristic hair abnormalities the
diagnosis of NTS is often delayed. Frequently, the con-
comitant atopic diathesis with elevated IgE levels, asthma,
and hay fever leads to misdiagnosis of severe atopic
dermatitis (AD). Other cases are initially misclassified as
Leiner disease––severe seborrhoic generalized dermatitis
(Hausser and Anton-Lamprecht, 1996). Histopathology
does not allow to distinguish NTS from disorders such as
psoriasis, because both conditions display focal para-
keratosis with psoriasiform epidermal hyperplasia, focal
absence of the granular layer, intraepidermal neutrophil
accumulation and at the functional level an impaired
epidermal barrier (Hausser and Anton-Lamprecht, 1996).
The list of differential diagnoses also includes erythrodermic
psoriasis, erythrokeratoderma variabilis, and acrodermatitis
enteropathica because of the perioral and perianal accent-
uation of erythema and scaling (Greene and Muller, 1985).
Recently, the diagnosis of NTS by molecular genetic
analysis became possible due to the mapping of the
respective gene locus on chromosome 5q32 (Chavanas
et al, 2000a) and subsequent identification of mutations in
the SPINK5 gene (Chavanas et al, 2000a, b; Sprecher et al,1Authors have contributed equally.
Abbreviations: AD, atopic dermatitis; hBD-2, human b-defensin 2;
LEKTI, lympho-epithelial Kazal-type inhibitor; NTS, Netherton
syndrome; PTC, premature termination codon
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2001; Komatsu et al, 2002; Bitoun et al, 2002a, b). SPINK5
encodes a serine protease inhibitor called LEKTI (lympho-
epithelial Kazal-type inhibitor) (Ma¨gert et al, 1999), a
cysteine-rich protein consisting of 15 Kazal-type-like in-
hibitory domains (Ma¨gert et al, 2002a). Recombinant human
LEKTI inhibits in vitro a battery of serine proteases including
plasmin, trypsin, subtilisin A, cathepsin G, and elastase
(Ma¨gert et al, 2002b; Mitsudo et al, 2003), but the exact
assignment of specific inhibitory activity to individual
domains remains to be determined. LEKTI mRNA is present
in epidermis, pilosebaceous units (Komatsu et al, 2002) and
other tissue, but its precise biological function in vivo
remains unclear. We developed a novel monoclonal anti-
body to assess the effects of SPINK5 mutations in NTS
patients on the expression of epidermal LEKTI. In addition,
we wondered how LEKTI mutations disturb keratinization
and in view of the epidermal hyperplasia studied the
behavior of transglutaminases which play a key role for
cross-linking of the cornified envelope and thus for
epidermal differentiation. In view of the susceptibility to
severe infections we analyzed the expression of the anti-
microbial peptides human b-defensin 2 (hBD-2) and SKALP/
elafin. Here, we report two known and three novel SPINK5
mutations, all of them resulting in epidermal LEKTI
deficiency. In addition, we found a differential and remark-
ably discordant expression of transglutaminases1 and 3 in
NTS, which may explain the disturbed epidermal barrier,
and we observed the unexpectedly strong presence of
hBD-2 and elafin in NTS.
Results
Mutation analyses Mutation analysis by direct sequencing
revealed three novel and two published mutations (Table I).
The novel mutations are an insertion of T in patient 1, a two-
bp deletion in family H (patient 3.1 and 3.2; Fig 1) and a
recurrent acceptor splice site mutation in patient 5, and
siblings 2.1/2.2, who are homozygous for this putative
mutation (Fig 2). Patient 1 is homozygous for 715insT, which
leads to a frameshift resulting into a premature termination
codon (PTC) after six codons. The two-bp deletion
398delTG in exon 5 immediately results into a PTC. This
mutation in family H was transmitted to both patients 3.1
and 3.2 by their father. The novel mutation 1432–13 G>A
affects intron 15 near the intron–exon boundary to exon 16.
A detailed analysis of this mutation using the Splice Site
Prediction Programm by Neural Network (http://www.
fruitfly.org/seq_tools/splice.html and http://www.cbs.dtu.dk/
services/NetGene2/) showed that the wild-type sequence
cggtttcttaaagTCAA (splice site underlined) was changed to
cagtttcttaaagTCAA. This predicts an additional very strong
acceptor splice site 10 bp upstream of the wild-type aAG
acceptor splice site used for exon 16 (Fig 2). This mutation
was found in the heterozygous and homozygous state in
two independent patients of different ethnic origins (Austria,
Bosnia). In the family from Bosnia this mutation was
transmitted by both (non-consanguineous) parents. It was
not found in 80 normal chromosomes. All novel mutations
predict a significant truncation of the LEKTI polypeptide.
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LEKTI antibody From one fusion, 24 positive hybridoma
clones were selected and subcloned by three to four rounds
of limiting dilution. Eight surviving subclones were isotyped
and characterized by immunoblotting or immunocyto-
chemistry. Anti-LEKTI (1D6G8, 4G12B1, 2A3A12, 1C11G6,
2A7C3, and 3B12F6) belonged to the IgG1 subclass. The
remaining MAbs 3E5H4 and 2A7C4 were of IgG2 subclass.
Because of its robust immunoreaction in immunoblotting
1C11G6 was subsequently used as the detecting antibody
in immunohistochemistry. To identify the LEKTI domains
recognized by 1C11G6, we performed a western blot
analysis on purified LEKTI domains 6-9 or Sf9 cell lysates
containing rLEKTI domains 1–6, 9–12, or 13–15 (Fig 3).
1C11G6 reacted strongly with precursor LEKTI, LEKTI
domains 1–6, 6–9, 9–12, and weakly with 13–15. These
data suggested recognition of a repetitive or recurring
epitope that is present at least on domains 6–9.
LEKTI immunoblot analysis Detection of LEKTI in hair
roots by immunoblot analysis showed a strong signal in
healthy individuals (n¼ 5) visualizing the full length protein at
140 kDa. At least three further LEKTI fragments could be
seen at approximately 110, 90, and 60 kDa, respectively
(Fig 4; lanes 1 and 2). In NTS patients (patient 2.1; 2.2; 5 and
1) neither the full length form of LEKTI nor the cleaved
products were present (Fig 4; lanes 3–6) demonstrating
absence of full length protein and of cleaved LEKTI
products in NTS hair roots.
Histochemical transglutaminase activity Skins of normal
adults showed pericellular linear transglutaminase activity
confined to the uppermost two or three nucleated cell layers
(Fig 5a). In NTS, however, the activity was enhanced in
terms of intensity of fluorescence after visualization of
incorporated substrate and there was a very broad zone of
enzymatic activity including most of the suprabasal layers
(Fig 5b–f).
Immunohistochemistry Immunological detection of LEKTI
in normal skin (Fig 6a–f) and in skin from psoriasis vulgaris
patients (Fig 6g) was confined to the granular layer giving a
predominantly cytoplasmic reaction occasionally mixed
with a pericellular signal. Hair follicles stained positive (Fig
6f). Immunhistochemical double staining of involucrin and
LEKTI in normal hair follicles revealed strong presence of
LEKTI in the inner root sheath (Fig 7a–d). All NTS patients
showed a striking absence of LEKTI immunoreactivity in the
epidermis (Fig 6h–l).
Transglutaminase1 protein (as detected by immuno-
histochemistry) showed a pericellular distribution of the
uppermost two to three nucleated epidermal cell layers and
no immunoreactivity in the cornified layer in normal skin. In
contrast NTS skin consistently showed a grossly enlarged
distribution zone including most of the suprabasal cell
layers. The histochemical localization of transglutaminase1
activity at pH 7.4 in normal and NTS skin was highly
comparable with the respective distribution of the protein
(not shown).
Immunoreactive transglutaminase3 in normal skin ap-
peared as a blurred band along the border of granular and
cornified layer in normal skin (Fig 8a). Only the uppermost
nucleated layer was involved showing a mixed pericellular
and cytoplasmic staining. In contrast to transglutaminase1,
transglutaminase3 was also present in the cornified layer
occupying the lower third of the stratum corneum. NTS skin,
however, showed very faint or absent transglutaminase3
immunoreactivity (Fig 8c–h). As an exception, patient 3.1
(Fig 8h), the clinically less affected sister of patient 3.2,
showed a transglutaminase3 expression comparable with
that of normal skin. Elafin was absent in normal epidermis
(Fig 9a). In contrast, psoriatic and NTS skin (Fig 9a–f)
showed a clear pericellular linear expression of the upper-
most three to five nucleated keratinocyte layers below the
cornified layer. Again, patient 3.1 (Fig 9f) showed elafin
absence comparable with normal skin. With hBD-2, no
immunostaining was achieved in normal skins (Fig 10a). In
contrast, psoriatic skins showed multilamellar expression
strictly confined to the cornified layer (Fig 10b). NTS skins
also expressed hBD-2 in the cornified layer, albeit less
intense than seen with psoriatic skins (Fig 10c–e). Again, as
Figure 1
(a) Direct sequencing results of the SPINK5 gene obtained in
patient 2.1. The patient is heterozygous for a novel two bp deletion
in exon 5 that bridges two codons. This results immediately in a
premature termination codon (PTC). Exon 25 shows two changes: the
heterozygous and conservative polymorphism L786, and a missense
mutation leading to a PTC. This mutation has been reported earlier in
other NTS patients (Chavanas et al, 2000b). (b) Representative
pedigree of NTS-family H. The novel 398delTG was inherited from
the father, R790X from the mother. The unaffected brother Jo.H.
harbored neither mutation and was homozygous for the wild-type.
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an exception patient 3.1 (Fig 10f), showed only very faint
expression of hBD-2.
Other differentiation markers Involucrin in normal skin
was restricted to the granular layer with a granular
pericellular staining and interspersed perinuclear patches
(not shown). Psoriatic skins expressed involucrin in up to six
cell layers below the cornified layer in a granular pericellular
fashion. NTS skins showed a mixture of both patterns (not
shown). Annexins I and II showed a patchy pericellular
immunostaining of basal and some suprabasal keratino-
cytes (not shown). In contrast, psoriatic skin showed a
pericellular expression of almost all suprabasal cell layers.
NTS patients showed a mixture between normal and
psoriatic skin (not shown). No significant difference was
noted between the siblings 3.1 and 3.2 with any of the
above markers (not shown).
Discussion
We have identified two published (Chavanas et al, 2000b)
and three novel SPINK5 mutations in NTS patients. Two
novel mutations 398delTG (exon 5) and 715insT (exon 9)
are frameshift mutations, which immediately or after six
codons, respectively, cause a PTC. The PTC in exon 5
predictably truncates the LEKTI polypeptide in the second
of 15 inhibitor domains and represents an equivalent to a
functional null allele. 715insT in exon 9 predictably truncates
the peptide within the inhibitory LEKTI domain 4. The third
Figure 2
Direct sequencing results of the
SPINK5 gene obtained in patient 5,
2.1 and 2.2. The novel mutation 1432–13
G4A in intron 15 is heterozygous in
patient 5 and homozygous in patient 2.1
and his sister 2.2. Schematic representa-
tion of the proposed effect of the novel
putative mutation (below). The base ex-
change creates a strong additional splice
site upstream of the proper/obligatory
correct splice site. Alternative utilization
of this novel splice site would lead to a
3’extension of exon 16 and a frameshift
resulting in an premature termination
within exon 16.
Figure 3
Specificity of LEKTI monoclonal antibody in immunoblot analysis.
Full length recombinant LEKTI or lysates from Sf9 cells expressing
different LEKTI fragments were subjected to SDS-PAGE and electro-
blotting onto nitrocellulose and detected with LEKTI mAb 1C11G6.
(Lane 1) precursor rLEKTI (125 kDa) (1.0 mg); (lane 2) cell lysate
containing LEKTI domains 1–6 (43 kDa); (lane 3) purified rLEKTI do-
mains 6–9 (35.5 kDa) (1.0 mg); (lane 4) cell lysate containing rLEKTI
domains 9–12 (35.2 kDa); (lane 5) cell lysate containing (50 mg) rLEKTI
domains 13–15 (30.6 kDa); (lane 6) cell lysate from uninfected cells (50
mg). The additional lower Mw bands in lanes 2 and 4 may reflect
proteolytic breakdown products of rLEKTI fragments.
Figure4
Immunoblot results of LEKTI in human hair roots. The figure shows
the immunoblot analysis in hair roots of two normal individuals (lanes 1
and 2) and of four NTS patients (lanes 3–6: patient 5; 2.1; 2.2; 1). Lane 7
shows rLEKTI (130 ng). In hair roots from normal individuals full length
protein is visualized at 140 kDa and at least three further cleaved
products can be seen. In contrast in the four NTS patients neither the
full length LEKTI nor the cleaved products are present.
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novel mutation in intron 15––1432-13 G>A––creates a
putative acceptor splice site only 10 bp upstream of the
orthodox splice site. Usage of the alternative splice site will
result in a frame shift and a PTC in exon 16 predictably
leading to a truncation after Kazal-type-like domain 7. Since
we had no cell cultures of NTS patients available we could
not evaluate the effect of the splice site mutation at mRNA
level, but immunoblot analysis of NTS hair roots demon-
strated absence of SPINK5 gene products in all four NTS
patients analyzed. In contrast, immunoblot analysis of
healthy hair roots gave a strong signal of full length LEKTI
and of at least three smaller LEKTI fragments. These data
provide evidence for a proteolytic processing of LEKTI
occurring in vivo and are in agreement with in vitro results
obtained in keratinocyte cultures likewise showing cleavage
of LEKTI (Bitoun et al, 2003). Furthermore, all mutations
were associated with a dramatic lack of immunhistochem-
ical LEKTI-staining in the epidermis of the respective NTS
patients. The newly developed antibody against recombi-
nant LEKTI presumably recognizes already epitopes in
LEKTI domain 1–6, but––except for patient 1––all NTS
patients show PTC mutations after domain 6. The homo-
zygous mutation 2468insA in exon 26 in patient 4 even
predicts a polypeptide of 11 complete domains and a nearly
complete domain 12. The striking lack of epidermal LEKTI
staining in all NTS patients and our immunoblot results
therefore suggest nonsense-mediated decay, a rapid and
complete proteolytic breakdown of truncated LEKTI protein,
or possibly, both. Moreover, it emphasizes the potential
usefulness of the antibody for future diagnosis of NTS in
clinical practice utilizing either immunhistochemistry of skin
biopsies or immunoblot analysis of plucked hair roots.
Surprisingly, we observed a differential expression of
transglutaminases in the epidermis of NTS patients.
Although transglutaminase1 activity was found in a much
enhanced zone affecting almost the entire suprabasal
epidermis, a dramatic decrease was found for transgluta-
minase3. In view of the eminent role of transglutaminases
for the assembly of the cornified envelope and for epidermal
differentiation, the behavior of transglutaminase1 was
expected and a similar pattern was observed by us in
psoriatic skin likewise featuring epidermal hyperplasia.
Rather unexpected was the dramatic lack of transglutami-
nase3, which may account for the markedly impaired
epidermal barrier in NTS. We performed a preliminary
immunfluorescence study of transglutaminase3 expression
in a small set of five patients with AD (data not shown).
There was a strong signal of transglutaminase3 in the
stratum corneum of all patients which may implicate a
different pathophysiology of the epidermal barrier defect in
AD and NTS. A recent study comparing transglutaminase5
expression with proliferating (keratin 14) and differentiating
(transglutaminase3) markers in different diseases such as
psoriasis, ichthyosis vulgaris, and lamellar ichthyosis, found
a completely misregulated expression of transglutami-
nases3 and 5 in Darier’s disease (Candi et al, 2002). These
authors simultaneously observed total absence or over-
expression of transglutaminase3 in different areas of the
same lesion. Obviously, NTS is the first skin disorder
reported showing consistent and complete lack of trans-
glutaminase3 expression. Initially, we attributed the lack of
transglutaminase3 to a disturbance of epidermal differentia-
tion; however, other differentiation markers and cornified
envelope proteins such as involucrin showed only subtle or
no expression differences.
Interestingly, we found proteins expressed in NTS
epidermis that are normally absent in normal skin, namely,
elafin and hBD-2. Elafin/SKALP, a small serine proteinase
inhibitor directed against polymorphonuclear leukocyte
(PMN)-derived enzymes such as elastase and proteinase
Figure 5
Visualization of transglutaminase1 ac-
tivity in skin sections of Netherton
syndrome patients. (a) Strong pericellu-
lar epidermal transglutaminase1 at pH 7.4
in normal skins spanning 2–3 layers of the
str. granulosum. In contrast skin from NTS
patients (b–f: patient 4; 1; 3.2; 3.1; 2.1)
shows a grossly enlarged activity zone.
The pericellular linear distribution pattern,
however, is well preserved, the activity
appears enhanced. (Magnification bar
corresponds to 30 mm.)
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3, contains transglutaminase substrate domains for cross-
linking to extracellular and cell envelope proteins (Schalk-
wijk et al, 1999). Elafin/SKALP is constitutively expressed in
several epithelia that are continuously subjected to inflam-
matory stimuli, such as the oral cavity and the vagina where
it colocalizes with transglutaminase1. Pseudostratified
epithelia, simple/glandular epithelia and normal epidermis,
however, are negative (Pfundt et al, 1996). Certain skin
conditions, however, show epidermal elafin expression with
psoriasis being the most prominent (Schalkwijk et al, 1993;
Nonomura et al, 1994; Streit et al, 1995). Remarkably, the
NTS patient 3.1 showed only very faint immunostaining for
elafin. Since she appeared to be clinically much less
affected than her elafin-expressing sister this difference
might reflect her current lower disease activity. In fact,
decreasing elafin/SKALP serum levels have been reported
in psoriasis in correlation with the improvement of the PASI
score during cyclosporin A treatment (Alkemade et al,
1995). It is currently believed that inflammatory mediators
such as IL-1b or TNF-a secreted by dermal neutrophils may
be involved in overexpression of elafin in keratinocytes; this
could protect the epidermis from degradation by dermal
neutrophil infiltration. Recent findings suggest that elafin
cannot only be induced by bacterial lipopolysaccharides
Figure 6
Visualization of LEKTI distribution in
normal and NTS skin. Normal skin (a–f)
shows a predominantly cytoplasmic, par-
tially pericellular presence along the stra-
tum granulosum (b and c). Hair follicles
show a mixed pericellular/cytoplasmic
immunostaining in the inner root sheath
(e and f). Application of preimmune serum
gave negative results (a and d). Psoriatic
skin shows pronounced cytoplasmic
staining in a broadened subcorneal zone
(g). In contrast, NTS-patients (h–l: patient
4; 2.1; 1; 3.1; 3.2) showed absent or only
faint patchy cytoplasmic staining indicat-
ing a dramatic reduction of epidermal
LEKTI. (Magnification bar corresponds to
30 mm.)
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but it also exerts microbicidal action, comparable with anti-
microbial defensin-like peptides (reviewed in Sallenave,
2002). The obvious upregulation of elafin in NTS skin might
be regarded as a compensatory mechanism to provide both
anti-microbial activity and compensation for lost proteinase
inhibitor activity due to LEKTI deficiency.
Similarly, the expression of the professional anti-micro-
bial peptide hBD-2 is intriguing. It plays an important role in
the skin innate immune system and is markedly upregulated
in psoriatic skin (Harder et al, 1997; Huh et al, 2002). In
contrast, skin of patients with AD shows no or faint
expression of hBD-2 (Ong et al, 2002). Since psoriasis
patients have a strikingly reduced rate of viral and bacterial
skin infections in comparison with patients with AD (7% vs
30%) (Christophers and Henseler, 1987) it is currently
assumed that the overexpression of hBD-2 and other anti-
microbial peptides protect psoriatic skin from infection
despite chronic inflammation (Ong et al, 2002). NTS is
currently believed to be related to AD due to its chronic
dermatitis and atopic features. A number of reports
concerning large series of patients with NTS (Traupe,
1989; Bitoun et al, 2002a and b) mention that like in AD
NTS patients suffer frequently from skin infections, often
caused by Staphylococcus aureus. A recent report suggests
that this property may be related to selective antibody
deficiency to bacterial polysaccharide antigens (Stryk et al,
1999). This was not investigated in the present study, but it
is obvious that the high epidermal expression of elafin and
hBD-2 in NTS does not seem to prevent skin infections
effectively although its expression pattern resembles that of
psoriasis.
The marked lack of LEKTI staining in all five NTS patients
and missing of LEKTI in hair roots suggests that LEKTI
deficiency is a hallmark of NTS. These findings are
consistent with a recent study (Bitoun et al, 2003). The
consequences of the LEKTI deficiency, however, remain an
enigma. Komatsu et al (2002) demonstrated elevated
hydrolytic activity in the stratum corneum in NTS patients
and suggested a major role for LEKTI in normal desquama-
tion by controlled breakdown of desmosomal proteins.
Accordingly, LEKTI deficiency would cause enhanced
proteolytic activity in the epidermis, subsequent enhanced
breakdown of desmosomal proteins and hyperdesquama-
tion (Komatsu et al, 2002). Although it is true that inflamed
areas in NTS skin show coarse flaking we would like to point
out that the fine desquamation found in most patients even
in ILC does not appear to fit the above pathomechanism.
LEKTI inhibits in vitro a battery of proteases (Mitsudo et al
2003) some of which have the potential to process and
activate proinflammatory cytokines. Given the prominent
inflammatory features of NTS it appears equally possible
that LEKTI deficiency primarily causes proteinase-mediated
inflammation with epidermal hyperplasia and impaired
Figure 7
Immunohistochemical visualization of involucrin and LEKTI in hair
follicles of normal individuals. (a) FITC anti-rabbit: Immunofluores-
cence staining with polyclonal rabbit anti-involucrin antibody shows
both staining of the outer root sheath (ORS) and of the inner root sheath
(IRS) of the hair follicle. (b) TexasRed-anti-mouse: A strong signal for
LEKTI is seen in the IRS. (c) Translucent microscope of the hair follicle
(HS  hair shaft). (d) Overlay image FITCþTexasRed: Double staining
of involucrin and LEKTI demonstrates that LEKTI is predominantly
present in the IRS. (Magnification bar corresponds to 30 mm.)
Figure 8
Immunohistochemical detection of
transglutaminase3 protein in normal
skin and NTS. (a) Normal skin shows a
narrow band between granular and corni-
fied layer. (b) Psoriatic skin shows a
similar pattern with interruptions. In con-
trast, NTS skins show a clear lack of
transglutaminase3 expression (c,d,f: pa-
tient 5; 4; 2.1) or very faint and scant
intracellular immunostaining (e.g., patient
1; 3.2). Remarkably, patient 3.2 (g), the
more severly affected sister of patient 3.1
(h), showed intracellular scanty staining in
3–5 cell layers below the cornified layer,
whereas in patient 3.1 (h) intense immu-
nostaining is seen at the boarder between
granular and cornified layer and within the
cornified layer. (Magnification bar corre-
sponds to 30 mm.)
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epidermal barrier as secondary features. This speculation
however, warrants further investigation.
In conclusion, we have shown that LEKTI can be
detected by immunoblot analysis of normal human hair
roots but it was missing in four NTS patients and that
SPINK5 mutations in NTS are associated with epidermal
LEKTI deficiency at protein level. The surprising differential
expression of transglutaminases discloses a profound
alteration of epidermal differentiation and may account for
the impaired epidermal barrier.
Materials and Methods
Patients We ascertained five different NTS families including
seven affected individuals. Local ethical committee approval and
informed consent was obtained for the study. The diagnosis of NTS
was based on the presence of CIE-like ichthyosis or ILC, hair shaft
abnormalities including trichorrhexis invaginata or nodosa, or pili
torti, elevated IgE levels, allergies, history of recurrent bacterial
infections, malnutrition, failure to thrive, and neonatal dehydration
(online Table S1). All patients exhibited typical skin involvement and
trichorrhexis invaginata. Four mm punch biopsies were taken and
Figure 9
Immunohistochemical detection of
elafin in normal skin, psoriatic skin
and NTS. (a) Normal skin: no significant
immunostaining. (b) Psoriatic skin shows
pericellular linear and continuous localiza-
tion in broad subcorneal zone layer (three
to five keratinocyte layers). (c–e: patient 1;
4; 3.2) NTS skin shows moderate to
strong pericellular elafin expression in a
subcorneal zone comprising maximally
three cell layers and slight staining in the
cornified layer. (f) Patient 3.1 showed no
significant elafin expression in contrast to
her clinically more severely affected sister
3.2 (compare with (e)). (Magnification bar
corresponds to 30 mm.)
Figure 10
Immunohistochemical detection of hu-
man b-defensin 2 in normal skin, psor-
iatic skin and NTS. (a) Normal skin: no
significant immunostaining. (b) Psoriatic
skin shows strong expression of hBD2 in
a multilamellar sharply defined fashion
restricted to the cornified layer. (c–e:
patient 1; 4; 3.2) NTS skin shows moder-
ate hBD2 expression. (f) Patient 3.1
showed no significant hBD2 expression
in contrast to her clinically more severely
affected sister L.H. (compare with (e)).
(Magnification bar corresponds to 30 mm.)
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results obtained compared with skin biopsies from 30 normal
adults, three normal newborns, and five patients with classical
psoriasis vulgaris.
SPINK5 mutation analysis Genomic DNA was prepared from
peripheral blood leukocytes by standard procedures (Sambrook et
al, 1989). All 33 exons of the SPINK5 gene were amplified using
most of the published primer pairs (Chavanas et al, 2000b;
Sprecher et al, 2001). New primers were designed from the Homo
sapiens chromosome 5 partial sequences (GenBank accession no.
AC116334, AC008722) and from the partial sequences of SPINK5
(GenBank accesion no. Aj276578, Aj391235–Aj391241, AF295783,
AF295784) for exons 7–16 (online Table S2). Individual PCR
reactions were performed using the above specified primers with
Taq DNA polymerase recombinant (Invitrogen Life Technologies,
Karlsruhe, Germany), 5% dimethyl sulfoxide (Sigma-Aldrich Che-
mie GmbH, Steinheim, Germany), 0.5 M Betaine (dto). Genomic
DNA (100 ng per mL) of affected individuals was amplified using the
Biometra Thermocycler TGradient. For all exons PCR conditions
were as follows: 941C 4.30 min followed by 35 cycles at 561C
1 min, 721C 1 min, 941C 45 s; and a final extension step at 721C for
10 min. Mutation analysis was performed by direct sequencing of
amplified exons using Big Dye Terminator Protocol and Reaction
Clean-up for 96-well Microtiter Plates with Sephadex G-50.
Sequences were directly read out in an ABI 3700 (Applied
Biosystems, Foster City, California). The following electronic data-
banks were used: http://www.ncbi.nlm.nih.gov/PubMed/; http://
www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi; http://
genius.embnet.dkfz-heidelberg.de/menu/; http://www.cbs.dtu.dk/
services/NetGene2/; http://www.fruitfly.org/seq_tools/splice.html.
Data analysis was performed using Chromas Version 1.43 (Conor
Mc Carthy, Griffith University, Brisbane, Queensland, Australia).
Histochemical transglutaminase assay This screening assay
allows to differentiate between full, residual and lost epidermal
transglutaminase1 activity (Raghunath et al, 1998). Briefly, cryo-
sections were incubated with the transglutaminase substrate
biotinylated cadaverine (Molecular Probes, Leiden, The Nether-
lands) in Tris buffer pH 7.4 in the presence of calcium ions.
Incorporated substrate was visualized using streptavidin DTAF.
Slides were viewed with an Axioscope 2 and digital images taken
using an Axiocam HR video camera and Axiovision 3.0 software (all
Carl Zeiss, Jena, Germany).
Immunohistochemical localization of transglutaminase1,
transglutaminase3 and other proteins Acetone fixed cryosec-
tions (201C for 10 min) were incubated with mouse MAb BT-621
against human keratinocyte transglutaminase1 (Biomedical Tech-
nologies, Stoughton, Massachusetts) 1:40 for 16 h at 41C or rabbit
anti-transglutaminase3 diluted 1:100 (kindly provided by Dr Soo-
Youl Kim, NIH). Transglutaminase1 antibody was detected by a
two-step procedure using biotinylated goat anti-mouse 1:400 for
90 min (Jackson ImmunoResearch Laboratories, Inc., West Grove,
Pennsylvania) and streptavidin DTAF (Jackson ImmunoResearch
Laboratories, Inc., West Grove, Pennsylvania) 1:100 for 30 min. The
transglutaminase3 antibody was visualized using swine anti-rabbit
FITC 1:20 (Jackson ImmunoResearch Laboratories, Inc., West
Grove, Pennsylvania). For the detection of other proteins (except
elafin) cryosections were fixed in methanol. Sections were either
incubated with rabbit-anti-involucrin (CellSystems Biotechnologie
Vertrieb GmbH, St. Katharinen, Germany) diluted 1:200, rabbit
antibodies against elafin 1:2000 (Peptide Institute, Inc., Minoh-
shi Osaka, Japan), rabbit-anti-annexin I 1:200, and mouse-anti-
annexin II 1:400 (both: Zymed, San Francisco) or rabbit-anti-hBD-2
1:2000 (Peptide Institute, Inc., Minoh-shi Osaka, Japan), respec-
tively, for 16 h at room temperature. Rabbit-antibodies were
detected with FITC-goat anti-rabbit IgG (Jackson Immuno-
Research Laboratories); mouse-antibodies with FITC-goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories) both diluted
1:100.
Production and characterization of monoclonal LEKTI anti-
body Eight-wk-old BALB/c mice (Harlan Technology, Chicago)
were primed i.p. with 50 mg of recombinant LEKTI (Mitsudo et al,
2003) in complete Freund Adjuvant and boosted at 3-wk intervals
with 25 mg of antigen in complete Freund Adjuvant. Spleen cells
harvested 3 d after the fourth immunization were fused with
myeloma cells (P3  63-Ag8.653) and antibody-secreting hybrids
were identified 1 wk later by a capture ELISA using purified rLEKTI
as the antigen. Clones secreting desirable antibody were subjected
to limiting-dilution cloning to isolate monoclones and isotyped
(Zymed Labs, Inc., S. San Francisco); ascites was produced in
BALB/c mice. To determine the LEKTI regions recognized by
different Mabs, immunoblot analysis was done using purified
rLEKTI domains 6–9 or Sf9 cell lysates containing rLEKTI domains
1–6, 9–12, or 13–15. Briefly, proteins were mixed with 2  gel
loading buffer (4% SDS, 20% glycerol, 120 mM Tris–HCl, pH 6.8%,
0.01% bromophenol blue, 2% b-mercaptoethanol), heated to 951C
for 5 min, and separated by SDS-PAGE (6%) (Mitsudo et al, 2003).
Proteins were transferred from polyacrylamide gel onto nitrocellu-
lose membranes (Schleicher & Schull BioScience, Inc., Keene,
New Hampshire) using a mini-transblot electrophoretic cell
(BioRad, Hercules, California) at 25 V for 16 h at 41C. After a
blocking step (16 h with 3% BSA in Tris buffered saline)
membranes were subsequently incubated with mouse ascites
1:1000 for 2 h at room temperature, horseradish peroxidase-
conjugated goat-anti-mouse IgG (Hþ L) 1:2500 (Jackson Immu-
noResearch Laboratories, Inc., West Grove, Pennsylvania). Finally,
bound LEKTI antibody was visualized by exposure to Kodak X-AR5
films (Eastman Kodak Company Scientific Imaging Systems,
Rochester, New York) using chemiluminescence (ECL system,
Amersham Bioscience Corporation, Piscataway, New Jersey).
Immunoblot analysis of human hair samples Twenty scalp hairs
were each plucked from five healthy voluntary individuals and from
four NTS patients (patient 1; 2.1; 2.2 and 5) and hair roots were
transferred into 40 mL lysis buffer containing 1% Triton X-100 in
PBS, 1 mM Pepstatin, 1 mM E64, 2 mM Pefabloc (all proteinase
inhibitors from Sigma, Deisenhofen, Germany). Subsequently,
these samples were kept at 41C for 20 min, heated at 991C for
10 min and then stored at 201C before western blot analysis.
For immunoblot analysis samples were subjected to electro-
phoresis using 25 mL of sample-mixture from each normal control
individual and 40 mL of samples from each NTS patient. For
electrophoresis 7.5% acrylamide gels under reducing condi-
tions were used and afterwards proteins were transferred onto a
PVDF-membrane (Immobilon P, Millipore, Eschborn, Germany) by
western blotting. For detection with LEKTI-specific antibodies the
membrane was saturated with 3% BSA in TBS for 1 h, incubated
with the primary antibody (mAb 1C11G6 1:1.000) for 2 h and
afterwards with peroxidase-conjugated secondary anti-mouse
antibody (Sigma, Deisenhofen, Germany) for 1 h at room
temperature. Detection was performed using chemiluminescence
detection reagent Rotilumin (Roth, Karlsruhe, Germany) following
manufacturer’s instructions.
Immunhistochemical localization of LEKTI Acetone-fixed cryo-
sections were airdried and blocked with normal goat serum 10%,
or with BSA 2% in PBS for blocking of endogenous peroxidase,
respectively. Sections were then incubated with mAb 1C11G6
1:200 for 16 h at RT. LEKTI antibody was either detected with
FITC-goat anti-mouse antibody 1:100 (Jackson ImmunoResearch
Laboratories, Inc., West Grove, Pennsylvania) or a peroxidase
procedure using DAKO EnVision System (DAKO Corp., Carpinteria,
California) and counterstaining with Mayer’s hemalum. For involu-
crin/LEKTI double staining sections were incubated with mAb
1C11G6 1:100 and polyclonal rabbit anti-involucrin 1:1000 (BAb-
CO, Richmond, California) and antibodies were detected with both
TexasRed-goat anti-mouse antibody 1:100 and FITC-goat anti-
rabbit (both: Jackson ImmunoResearch Laboratories, Inc., West
Grove, Pennsylvania).
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